Top

Published in:

Open Access 01-12-2018 | Review

A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac

Authors: Fabiola Atzeni, Ignazio Francesco Masala, Piercarlo Sarzi-Puttini

Published in: Pain and Therapy | Issue 2/2018

Abstract

Diclofenac is widely used to manage chronic inflammatory and degenerative joint diseases such as osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and extra-articular rheumatism. Its various mechanisms of action make it particularly effective in treating nociceptive pain, but it is also an alternative for treating spinal and chronic central pain. Osteoarthritis and rheumatoid arthritis are the most frequently encountered arthritic conditions in adults. The management of nociceptive pain requires a sequential hierarchical approach, with the initial NSAID treatment being characterized by the replacement of one drug with another, or complete discontinuation usually because of insufficient pain control. OA- and RA-related pain is complex and multifactorial, and due to physiological interactions between the signaling of the central and peripheral nervous systems. The mechanisms of action of diclofenac make it particularly effective in treating both nociceptive pain and chronic central pain. This review underlines the mechanisms of diclofenac involved in chronic and acute joint pain, the most relevant adverse events.

Moore RA, McQuay HJ, Derry P, et al. Single dose oral diclofenac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2004;2:CD004768.

Gan TJ. Diclofenac: an update on its mechanism of action and safety profile. Curr Med Res Opin. 2010;26:1715–31.PubMed

Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheum. 1996;102:9–21.

Tegeder I, Lotsch J, Krebs S, et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther. 1999;65:533–44.PubMed

Wittenberg RH, Willburger RE, Kleemeyer KS, et al. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum. 1993;36:1444–50.PubMed

Ku EC, Lee W, Kothari HV, et al. Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986;80:18–23.PubMed

Giagoudakis G, Markantonis SL. Relationships between the concentrations of prostaglandins and the nonsteroidal antiinflammatory drugs indomethacin, diclofenac, and ibuprofen. Pharmacotherapy. 2005;25:18–25.PubMed

Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057–72.PubMed

Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclooxygenase- 1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563–8.PubMed

10.

Dennis EA. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem. 1994;269:13057–60.

11.

Walsh CE, Dechatelet LR, Thomas MJ, et al. Effect of phagocytosis and ionophores on release and metabolism of arachidonic acid from human neutrophils. Lipids. 1981;16:120–4.PubMed

12.

Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta. 1987;921:502–11.PubMed

13.

Nevalainen TJ, Gronroos JM, Kortesuo PT. Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis. Gut. 1993;34:1133–6.PubMedPubMedCentral

14.

Makela A, Kuusi T, Schroder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997;57:401–7.PubMed

15.

Triggiani M, Granata F, Frattini A, et al. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta. 2006;1761:1289–300.PubMed

16.

Singh N, Jabeen T, Sharma S, et al. Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2: structure of the complex formed between phospholipase A2 and diclofenac at 2.7A° resolution. Acta Crystallogr D. 2006;62:410–6.PubMed

17.

Clish CB, Sun YP, Serhan CN. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase. Biochem Biophys Res Commun. 2001;288:868–74.PubMed

18.

Tonussi CR, Ferreira SH. Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol. 1994;251:173–9.PubMed

19.

Fagni L, Bockaert J. Effects of nitric oxide on glutamate-gated channels and other ionic channels. J Chem Neuroanatomy. 1996;10:231–40.

20.

Armstead WM. Role of ATP-sensitive Kþ channels in cGMP-mediated pial artery vasodilation. Am J Physiol. 1996;270:H423–6.PubMed

21.

Soares AC, Duarte ID. Dibutyryl-cyclic GMP induces peripheral antinociception via activation of ATP-sensitive K(þ) channels in the rat PGE2-induced hyperalgesic paw. Br J Pharmacol. 2001;134:127–31.PubMedPubMedCentral

22.

Alves DP, Tatsuo MA, Leite R, et al. Diclofenac-induced peripheral antinociception is associated with ATP-sensitive Kþ channels activation. Life Sci. 2004;74:2577–91.PubMed

23.

Kaplan AA, Yurt KK, Deniz ÖG, Altun G. Peripheral nerve and diclofenac sodium: Molecular and clinical approaches. J Chem Neuroanat. 2018;87:2–11.PubMed

24.

Okuyama S, Aihara H. The mode of action of analgesic drugs in adjuvant arthritic rats as an experimental model of chronic inflammatory pain: possible central analgesic action of acidic nonsteroidal antiinflammatory drugs. Jpn J Pharmacol. 1984;35:95–103.PubMed

25.

Sacerdote P, Monza G, Mantegazza P, et al. Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations. Pharmacol Res Commun. 1985;17:679–84.PubMed

26.

Bjorkman RL, Hedner T, Hallman KM, et al. Localization of the central antinociceptive effects of diclofenac in the rat. Brain Res. 1992;590:66–73.PubMed

27.

Martini A, Bondiolotti GP, Sacerdote P, et al. Diclofenac increases beta-endorphin plasma concentrations. J Int Med Res. 1984;12:92–5.PubMed

28.

Bjorkman R, Hallman KM, Hedner J, et al. Nonsteroidal antiinflammatory drug modulation of behavioral responses to intrathecal N-methyl-d-aspartate, but not to substance P and amino-methyl-isoxazole-propionic acid in the rat. J Clin Pharmacol. 1996;36:20S–6S.PubMed

29.

Dong X-D. The analgesic action of topical diclofenac may be mediated through peripheral NMDA receptor antagonism. Pain. 2009;147:36–45.PubMed

30.

Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002;61:7–12.PubMed

31.

Gehrmann J, Matsumoto Y, Kreutzeberg GW. Microglia: intrinsic immunoeffector cell of the brain. Brain Res Rev. 1995;20:269–87.PubMed

32.

Yamazaki R, Kusunoki N, Matsuzaki T, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002;302:18–25.PubMed

33.

Na HK, Surh YJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem Pharmacol. 2003;66:1381–91.PubMed

34.

Sandri A. Spinal anti-inflammatory action of diclofenac. Minerva Med. 2016;107:167–72.PubMed

35.

Ayoub SS, Botting RM, Joshi AN, et al. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines. Mol Cell Biochem. 2009;327:101–10.PubMed

36.

O’Connor TM, O’Connell J, O’Brien DI, et al. The role of substance P in inflammatory disease. J Cell Phys. 2004;201:167–80.

37.

Tsuboi I, Tanaka H, Nakao M, et al. Nonsteroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes: up-regulation of TNF, IFN-gamma and IL-2, in contrast to down-regulation of IL-6 production. Cytokine. 1995;7:372–9.PubMed

38.

Henrotin Y, de Leval X, Mathy-Hartet M, et al. In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm Res. 2001;50:391–9.PubMed

39.

Mahdy AM, Galley HF, Abdel-Wahed MA, et al. Differential modulation of interleukin-6 and interleukin-10 by diclofenac in patients undergoing major surgery. Br J Anaesth. 2002;88:797–802.PubMed

40.

Sacerdote P, Carrabba M, Galante A, et al. Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti-inflammatory drugs indomethacin, diclofenac and naproxen. Inflamm Res. 1995;44:486–90.PubMed

41.

Gonzalez E, de la Cruz C, de Nicolas R, et al. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions. 1994;41:171–8.PubMed

42.

Voilley N, de Weille J, Mamet J, et al. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid sensing ion channels in nociceptors. J Neurosci. 2001;21:8026–33.PubMed

43.

Dorofeeva NA, Barygin OI, Staruschenko A, et al. Mechanisms of non-steroid anti-inflammatory drugs action on ASICs expressed in hippocampal interneurons. J Neurochem. 2008;106:429–41.PubMed

44.

Jones NG, Slater R, Cadiou H, et al. Acid-induced pain and its modulation in humans. J Neurosci. 2004;24:10974–9.PubMed

45.

Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford). 2000;39:3–12.

46.

Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185–99.PubMedPubMedCentral

47.

Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26–35.PubMed

48.

Salaffi F. Pain in osteoarthritis: assessment and impact on the disability. Reumatismo. 2003;55(4):19–37.

49.

Salaffi F, Carotti M, Stancati A, Grassi W. Health-related quality of life in older adults with symptomatic hip and knee osteoarthritis: a comparison with matched healthy controls. Aging Clin Exp Res. 2005;17(4):255–63.PubMed

50.

Mease PJ, Hanna S, Frakes EP, Altman RD. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment. J Rheumatol. 2011;38:1546–51.PubMed

51.

Dray A, Read SJ. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther. 2007;9:212.PubMedPubMedCentral

52.

Schaible HG, Schmelz M, Tegeder I. Pathophysiology and treatment of pain in joint disease. Adv Drug Deliv Rev. 2006;58:323–42.PubMed

53.

Salaffi F, Ciapetti A, Carotti M. The sources of pain in osteoarthritis: a pathophysiological review. Reumatismo. 2014;66:57–71.PubMed

54.

Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002;966:343–54.PubMed

55.

Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology. 2005;44:7–16.PubMed

56.

Porcheret M, Jordan K, Jinks C, Croft P. Primary care treatment of knee pain—a survey in older adults. Rheumatology (Oxford). 2007;46:1694–700.

57.

Juni P, Reichenbach S, Dieppe P. Osteoarthritis: rational approach to treating the individual. Best Pract Res Clin Rheumatol. 2006;20:721–40.PubMed

58.

Gore M, Sadosky A, Leslie D, Tai KS, Seleznick M. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther. 2011;33:1914–31.PubMed

59.

McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22:363–88.PubMed

60.

Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007;11(2):125–38.PubMed

61.

Chen YF, Jobanputra P, Barton P, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12:1–278.PubMed

62.

Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. Rockville: Agency for Healthcare Research and Quality (US), 2011.

63.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387(10033):2093–105.PubMed

64.

van Walsem A, Pandhi S, Nixon RM, Guyot P, Karabis A, Moore RA. Relative benefit–risk comparing diclofenac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis: a network meta-analysis. Arthritis Res Ther. 2015;17:66.PubMedPubMedCentral

65.

Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10:895–926.PubMedPubMedCentral

66.

Treede RD, Kenshalo DR, Gracely RH, Jones AK. The cortical representation of pain. Pain. 1999;79:105–11.PubMed

67.

Phillips K, Clauw DJ. Central pain mechanism in the rheumatic diseases. Arth Rheum. 2013;65:291–302.

68.

Burian M, Tegeder I, Seegel M, Geisslinger G. Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther. 2003;74:113–20.PubMed

69.

Vellani V, Franchi S, Prandini M, Moretti S, Castelli M, Giacomoni C, Sacerdote P. Effects of NSAIDs and paracetamol (acetaminophen) on protein kinase C epsilon translocation and on substance P synthesis and release in cultured sensory neurons. J Pain Res. 2013;6:111–20.PubMedPubMedCentral

70.

Kazis LE, Meenan RF, Anderson JJ. Pain in the rheumatic diseases. Investigation of a key health status component. Arthritis Rheum. 1983;26:1017–22.PubMed

71.

Atzeni F, Masala IF, Salaffi F, Di Franco M, Casale R, Sarzi-Puttini P. Pain in systemic inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol. 2015;29(1):42–52.PubMed

72.

Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2007;66:1195–201.PubMedPubMedCentral

73.

Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis: why wait? Explaining delays in seeking therapy for early arthritis. Nat Rev Rheumatol. 2012;8:190–1.PubMed

74.

Andersson ML, Svensson B, Bergman S. Chronic widespread pain in patients with rheumatoid arthritis and the relation between pain and disease activity measures over the first 5 years. J Rheumatol. 2013;40:1977–85.PubMed

75.

Atzeni F, Cazzola M, Benucci M, Di Franco M, Salaffi F, Sarzi-Puttini P. Chronic widespread pain in the spectrum of rheumatological diseases. Best Pract Res Clin Rheumatol. 2011;25:165–71.PubMed

76.

Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2010;152:S2–15.PubMedPubMedCentral

77.

Raychaudhuri SP, Raychaudhuri SK, Atkuri KR, Herzenberg LA, Herzenberg LA. Nerve growth factor: a key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum. 2011;63:3243–52.PubMed

78.

Schaible HG, von Banchet GS, Boettger MK, et al. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci. 2010;1193:60–9.PubMed

79.

Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013;31(5):731–8.PubMed

80.

Boers M, Verhoeven AC, Markusse HM, et al. Randomized comparison of combined step-down prednisolone, methotrexate, and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309–18.PubMed

81.

Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology. 2012;51(Suppl 5):v22–30.PubMed

82.

Ramiro S, Radner H, van der Heijde D, et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev. 2011;(10):CD008886.

83.

Wienecke T, Gotzsche PC. Paracetamol vs nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2004;1:CD003789.

84.

Whittle SL, Colebatch AN, Buchbinder R, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e initiative. Rheumatology (Oxford). 2012;51:1416–25.

85.

Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008921.

86.

Joshi S, Rapoport AM. Diclofenac potassium for oral solution (CAMBIA^®) in the acute management of a migraine attack: clinical evidence and practical experience. Ther Adv Neurol Disord. 2017;10(4):217–26.PubMedPubMedCentral

87.

Hagen M, Baker M. Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017;33:1623–34.PubMed

88.

Derry S, Wiffen PJ, Kalso EA, et al. Topical analgesics for acute and chronic pain in adults—an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;5:CD008609.

89.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.

90.

Kuo HW, Tsai SS, Tiao MM, Liu YC, Lee IM, Yang CY. Analgesic use and the risk for progression of chronic kidney disease. Pharmacoepidemiol Drug Saf. 2010;19:745–51.PubMed

91.

Kontogiorgis C, Valikeserlis I, Hadjipavlou-Litina D, Nena E, Constantinidis TC. Use of non-selective non-steroidal anti-inflammatory drugs in relation to cardiovascular events. A systematic pharmacoepidemiological review. Curr Vasc Pharmacol. 2016;14:502–13.PubMed

92.

Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci. 1999;96:7563–8.PubMed

93.

Laporte JR, Ibanez L, Vidal X, Vendrell L, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27:411–20.PubMed

94.

Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Drugs. 2015;75:859–77.PubMedPubMedCentral

95.

Zerbini C, Ozturk ZE, Grifka J, Maini M, Nilganuwong S, Morales R, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005;21(12):2037–49.PubMed

96.

Roussel NA, Nijs J, Meeus M, Mylius V, Fayt C, Oostendorp R. Central sensitization and altered central pain processing in chronic low back pain: fact or myth? Clin J Pain. 2013;29(7):625–38.PubMed

97.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610.PubMedPubMedCentral

98.

Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 2):8–11.PubMed

99.

Maltusch A, Röwert-Huber J, Matthies C, Lange-Asschenfeldt S, Stockfleth E. Modes of action of diclofenac 3%/hyaluronic acid 2.5% in the treatment of actinic keratosis. J Dtsch Dermatol Ges. 2011;9(12):1011–7.PubMed

100.

Intini FP, Zajac J, Novohradsky V, Saltarella T, Pacifico C, Brabec V, Natile G, Kasparkova J. Novel antitumor platinum(II) conjugates containing the nonsteroidal anti-inflammatory agent diclofenac: synthesis and dual mechanisms of antiproliferative effects. Inorg Chem. 2017;56(3):1483–97.PubMed

Title: A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac
Authors: Fabiola Atzeni
Ignazio Francesco Masala
Piercarlo Sarzi-Puttini
Publication date: 01-12-2018
Publisher: Springer Healthcare
Published in: Pain and Therapy / Issue 2/2018
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI: https://doi.org/10.1007/s40122-018-0100-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Pain Intensity Factors Changing Breakthrough Pain Prevalence in Patients with Advanced Cancer: A Secondary Analysis of a Cross-Sectional Observational International Study

A Review of the Burden of Trauma Pain in Emergency Settings in Europe

Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study

Systematic Review of Pain Medicine Content, Teaching, and Assessment in Medical School Curricula Internationally

Trends of Co-Morbid Depression in Hospitalized Patients with Failed Back Surgery Syndrome: An Analysis of the Nationwide Inpatient Sample

Physical Therapy Approaches in the Treatment of Low Back Pain

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page